PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Only One in Four AAV Immunosuppression Starts Receive PJP Prophylaxis

ANCA-associated vasculitisPneumocystis jirovecii pneumoniaPJP prophylaxistrimethoprim/sulfamethoxazoledapsoneatovaquoneinhaled pentamidinerituximabcyclophosphamideMedicareretrospective cohorthealth disparitiesguideline concordancesocial determinants of health Rheumatology / Immunology

Background Information

Low PJP prophylaxis in AAV patients raises concern for infections.

Infections are a leading cause of complications in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and prophylaxis is underutilized. Prophylaxis was only used in 26% of cases, with lower use in females and those from high poverty areas. The study highlights disparities in prophylaxis utilization, but its claims-based data might suffer from misclassification and lacks causal inference. Address gaps in PJP prophylaxis to enhance outcomes for AAV patients.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Cao B, Hickson RP, Zhao X, Aspinall SL, Derebail VK, Hogan SL, Ehlert A, Thorpe JM, Falk RJ, Thorpe CT

Citation: Cao B, Hickson RP, Zhao X, et al. Association of Demographic, Economic, and Geographic Factors With Guideline-Concordant Infection Prophylaxis in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Kidney medicine. 2026;8(12):101538. doi:10.1016/j.xkme.2026.101538

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.